over one minute once a week
Use:
Acute leukemia
This drug shows significant use when combined with other oncolytic agents in Hodgkin's disease, non-Hodgkin's malignant lymphomas, and Wilms' tumor.
Comment:
The manufacturer recommends the dose.
100 mg orally twice daily is given to patients having solid tumors with neurotrophic tyrosine receptor kinase
Dose Adjustments
In the case of adverse reactions
When body surface area ≥1 m2
1st occurrence: 75 mg twice daily
2nd occurrence: 50 mg twice daily
3rd occurrence: 100 mg per day
If unable to tolerate 100 mg per day, permanently discontinue the dose
In the case of CYP3A4 inhibitors
Circumvent co-administration
In the case of strong CYP3A4 inducers
Don’t co-administer
If the effect is unavoidable, double the dose
In the case of mild hepatic impairment, no dosage adjustment is required
In the case of moderate to severe hepatic impairment, reduce the starting dose by 50%
In the case of mild to severe renal impairment, no dosage adjustment is required
Subcutaneous/Intravenous/Intratumoral: Preparations with 20,000 ng/mL lectin concentrations or 100 mcg/mL viscotoxins concentrations were used.
Subcutaneous/Intravenous:
Several times weekly dosing with 0.1–30 mg has been successful
A single oral dose of 20 to 30 mg/kg/day. As an alternative, administer 80 mg/kg as a single dose every three days (for solid tumours). Concomitant irradiation treatment: 80 mg/kg as a single dosage given every three days, starting at least 1 week before radiotherapy, is considered
In phase I/II clinical trials
In the first study, patients received BMS-753493 once a day on Days 1, 4, 8, and 11 of every 21 days at an initial dose of 5 mg intravenously.
In Study 2, patients received BMS-753493 once a day on Days 1-4 of every 21 days at an initial dose of 2.5 mg everyday intravenously.
Outcomes In all, two investigations involved the treatment of sixty-five individuals.
In Study 1, the maximum tolerated dosage (MTD) was 15 mg, while in Study 2, it was 26 mg.
Indicated for advanced solid tumors The drug is investigated in phase I trial for advanced solid tumors The administration dose is 2.5 mg/m2 is well tolerated by the patients for three weeks or six weeks off
When (BSA) body surface area <1 m2: 100 mg/m2 orally twice daily
BSA ≥1 m2: 100 mg orally twice daily
Continue until unacceptable toxicity or disease progression
Dose Adjustments
In case of mild hepatic impairment, no dosage adjustment is required
In case of moderate to severe hepatic impairment reduce the starting dose by 50%
In case of mild to severe renal impairment, no dosage adjustment is required
When (BSA) body surface area <1 m2: 100 mg/m2 orally twice daily
BSA ≥1 m2: 100 mg orally twice daily
Continue until unacceptable toxicity or disease progression
Dose Adjustments
In case of mild hepatic impairment, no dosage adjustment is required
In case of moderate to severe hepatic impairment reduce the starting dose by 50%
In case of mild to severe renal impairment, no dosage adjustment is required
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
Digital Certificate PDF
On course completion, you will receive a full-sized presentation quality digital certificate.
medtigo Simulation
A dynamic medical simulation platform designed to train healthcare professionals and students to effectively run code situations through an immersive hands-on experience in a live, interactive 3D environment.
medtigo Points
medtigo points is our unique point redemption system created to award users for interacting on our site. These points can be redeemed for special discounts on the medtigo marketplace as well as towards the membership cost itself.
Community Forum post/reply = 5 points
*Redemption of points can occur only through the medtigo marketplace, courses, or simulation system. Money will not be credited to your bank account. 10 points = $1.
All Your Certificates in One Place
When you have your licenses, certificates and CMEs in one place, it's easier to track your career growth. You can easily share these with hospitals as well, using your medtigo app.
